Shl Telemedicine Ltd. · SIX:SHLTN
Shl Telemedicine — FY2022 Earnings Presentation
19 slides from Shl Telemedicine's earnings presentation, May 11, 2023
Slide 1: SHL Telemedicine FY Results 2022 Presentation
SHL Telemedicine FY Results 2022 Presentation
Slide 2: Forward looking statements
Forward looking statements This presentation was prepared for the purpose of providing and presenting information in a summary only and cannot replace a review of the reports of SHL Telemedicine (hereinafter: "the Company"). Many of the statements included in this presentation, as well as oral state
Slide 3: SHL Telemedicine at a glance
SHL Telemedicine at a glance Years of knowledge 30 SHL is a leading provider and developer of advanced telehealth technology and services with unmatched 30 years of medical & ECG data-base Listed on Nasdaq: SHLT Swiss Stock Exchange: SHLTN 27% increase in 2022 revenues(*) interactions and data 3M re
Slide 4: Senior management
Senior management Yariv Alroy Co-Chairman Ehud Barak Co-Chairman Former Prime Minister of Israel Erez Nachtomy CEO Amir Hai CFO Jason Bottiglieri General Manager SHL Telemedicine USA Bernd Altpeter Managing Director SHL Germany Linus Drop Managing Director SHL Germany Yossi Vadnagra General Manager
Slide 5: 2021-2022: "we said and we delivered" in all territories
2021-2022: “we said and we delivered” in all territories 5
Slide 6: 2022 overview – Financial data
2022 overview – Financial data(*) REVENUES $59m 27% Adjusted EBITDA(**) $4.1m 35% R&D Gross Expenses $7.2m Operational Cash Flow Break Even level Same as 2021 CASH On HAND $18.7m )*( compared to 2021 in constant currency, Please see Supplemental Information at end of presentation for a description o
Slide 7: Germany – Telemedicine becoming Standard of care
Germany – Telemedicine becoming Standard of care REVENUES $13.4m 16% Adjusted EBITDA(*) Population of 82 million insureds Four Break even largest Health Insurance each serve 5-10 million insureds With the supporting regulation, substantial part of the market expected to transfer to telemedicine Remo
Slide 8: Germany – Back to growth
Germany – Back to growth SHL is the market leader in Germany and operates in a B2B model - managing and stabilizing chronic patients and saving costs for health insurers The company has agreements with leading health insurers, covering about 30% of the German health insurance market (about 25 millio
Slide 9: Germany – Virtual Visit service
Germany – Virtual Visit service: Penetrating a market of about 800 million annual physical doctor visits In Germany - an average of 10 physical visits per person to a doctor each year (*) Won a pan-European tender published by BARMER in summer of 2022 for the virtual visit service - a new 7-year con
Slide 10: USA - Penetration through unique technology
USA - Penetration through unique technology REVENUES $0.5m Adjusted EBITDA(*) $(3.0)m ECG repository 24/7 ecg review center Provider portal USA cardiologist network Cloud based Thousands of SmartHeart units already in use A unique personal full 12 Lead ECG, FDA cleared, in hospital quality (12 Lead
Slide 11: USA - faster progress than planned
USA - faster progress than planned Increase in uses of the SmartHeartplatform Already FDA cleared 510(k) process for OTC clearance Appointed CEO for SHL USA with increased activity in all channels 11
Slide 12: Israel – High contribution to the company's profitability and cash flow
Israel – High contribution to the company's profitability and cash flow Revenues B2C model about $40 $45.1m Average monthly fees 51% Adjusted EBITDA(*) $12.6m 25% Subscribers on service About50,000 6 years – average subscription length sale of cardiac monitoring services to consumers: personal 12 Le
Slide 13: Financials – P&L
Financials – P&L (in million) In USD million (except per share amount) FY 2022 FY 2021cc* Revenue for the period 59.0 46.4 Revenue by territories Germany 13.4 16.0 Israel 45.1 30.0 Others 0.5 0.4 Adjusted EBIT(**) (3.0) 1.4 Adjusted EBITDA(**) 4.1 6.4 Net Income (loss) 0.2 (13.3) EPS (Basic) attribu
Slide 14: Financials – Balance Sheet and Cash Flow
Financials – Balance Sheet and Cash Flow (in millions) In USD million FY 2022 FY2021 Cash and cash equivalents(*) 4.5 14.8 Short term bank investments 14.2 17.2 Total cash and short-term investments 18.7 32.0 Short term bank debt 2.2 1.8 Long term bank debts 13.0 17.2 Total debts 15.2 19.0 Capital a
Slide 15: 2021-2022: "we said and we delivered" in all territories
2021-2022: “we said and we delivered” in all territories 15
Slide 16: 2023 – expected events
2023 – expected events constant increase in the use of Virtual Visits Agreements with additional health funds for Virtual Visit services Publication of results study for use of Continued implementation of B2B model – Tier 1 customers Obtain FDA OTC clearance Start of B2C sales Increased profitabilit
Slide 17: Thank You
Thank You SHL telemedicine
Slide 18: Supplement Information – Reconciliation of Adjusted EBITDA and Adjusted EBIT
Supplement Information 18 Reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures Key figures (as reported): in USD million (except per share amounts) FY2022 FY2021 % change Reve
Slide 19: Supplement Information – Constant currency
Supplement Information 19 (1) Constant currency – to enable meaningful comparison between 2022 and 2021 results, 2021 results are also presented at 2022 constant currency exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR